Nefedova L. Development of content and technology of nasal composition for the treatment of acute rhinosinusitis

A literature analysis of the modern state of research in the field of medicine development for the treatment of acute rhinosinusitis has been carried out. It is determined that acute rhinosinusitis is a widespread condition among the population in Ukraine and the whole world. A marketing analysis of the Ukrainian medicine market for the treatment of acute rhinosinusitis conducted has determined that the percentage of antiviral Ukrainian medicines is 52 % (as of 2018). For the first time the content of the nasal spray based on a combination of active pharmaceutical ingredients for the local treatment of acute rhinosinusitis, which has etiotropic and symptomatic effects, has been theoretically grounded and experimentally confirmed. Respective excipients, such as buffer components and a viscosity-increasing agent, have been selected. A technology of pharmaceutical composition in the form of the nasal spray and techniques for its quality control have been developed. Physical and chemical properties of the combined nasal composition have been studied; the parameters for standardization of the formulation and techniques for quantitative analysis of the active pharmaceutical ingredients have been suggested. For the first time, the antiviral activity of para-aminobenzoic acid and its synergetic effect in the combination with ε-aminocaproic acid against influenza virus А/FM/1/47 (H1N1) was found experimentally during in vitro studies. Complex stability studies for the determination of shelf-life expiration for the nasal spray have been carried out. The drafts of quality control and technological regulation for the complex nasal combination under the conditional name of “Combinazol” have been developed.